# Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers

> **NCT05429385** · PHASE1 · WITHDRAWN · sponsor: **Shanghai Henlius Biotech**

## Conditions studied

- COVID-19

## Interventions

- **DRUG:** HLX70
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05429385
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-12-09
- **Primary completion:** 2021-09-06
- **Final completion:** 2021-09-18
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Sponsor strategy.
- **Last updated:** 2022-06-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05429385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05429385, "Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT05429385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*